Listen on the go
CORRECT!
Next question
touchONCOLOGY touchONCOLOGY
Ovarian Cancer

Domenica Lorusso, ESMO 2021: Relacorilant in Combination with Nab-paclitaxel for Patients with Recurrent Platinum-resistant Ovarian Cancer

Copy Link
Published Online: Oct 19th 2021

touchONCOLOGY joins Dr Domenica Lorusso (Rome, Italy), to discuss the improvements in progression-free survival in patients with recurrent platinum-resistant ovarian cancer using relacorilant in combination with nab-paclitaxel. (NCT03776812)

Question
Please summarise the randomized, open-label, phase II study presented at ESMO 2021 exploring progression-free survival in patients with recurrent platinum-resistant ovarian cancer using relacorilant, a selective glucocorticoid receptor modulator, in combination with nab-paclitaxel.

  • Rationale and aims of the study: 00:30-04:05
  • Primary endpoints and results: 04:05-06:17
  • Conclusions and impact on future treatment: 06:17-07:29

Disclosures: Domenica Lorusso has no financial or non-financial conflicts of interest to declare in relation to this video.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.

Filmed in coverage of the ESMO 2021 Annual Meeting.

Share this Video
Related Videos In Ovarian Cancer
Ovarian Cancer
Developed by Touch
Paul DiSilvestro, ESMO 2022: SOLO1/GOG-3004 trial – Olaparib for the treatment of advanced ovarian cancer – Overall survival findings at 7 years
Watch Time: 5 mins

The Phase III SOLO1/GOG-3004 trial (NCT01844986), investigated maintenance olaparib, which provided sustained benefit beyond the end of treatment in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation. Prof. Paul DiSilvestro (Brown University, Providence, RI, USA) joins touchONCOLOGY to discuss the efficacy and safety of maintenance olaparib, and overall survival findings at 7 years. […]

Ovarian Cancer
Developed by Touch
Ruth Perets, AACR 2022: Vibostolimab / Pembrolizumab Coformulation for the Treatment of Ovarian Cancer Naive to PD-1/PD-L1 Inhibitors
Watch Time: 4 mins

We were delighted to speak with Dr. Ruth Perets (Rambam Health Care Campus, Haifa, Israel) about the efficacy and safety findings of the phase 1 study comparing vibostolimab (vibo) plus pembrolizumab (pembro) given sequentially to the coformulation of vibo/pembro in ovarian cancer naive to PD-1/PD-L1 inhibitors. The abstract ‘Safety and efficacy of vibostolimab (vibo) plus […]

Ovarian Cancer
Domenica Lorusso, ESMO 2021: Relacorilant in Combination with Nab-paclitaxel for Patients with Recurrent Platinum-resistant Ovarian Cancer

touchONCOLOGY joins Dr Domenica Lorusso (Rome, Italy), to discuss the improvements in progression-free survival in patients with recurrent platinum-resistant ovarian cancer using relacorilant in combination with nab-paclitaxel. (NCT03776812) Question Please summarise the randomized, open-label, phase II study presented at ESMO 2021 exploring progression-free survival in patients with recurrent platinum-resistant ovarian cancer using relacorilant, a selective […]

Trending In Ovarian Cancer:

Paul DiSilvestro, ESMO 2022: SOLO1/GOG-3004 trial – Olaparib for the treatment of advanced ovarian cancer – Overall survival findings at 7 years
Ovarian Cancer
    • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72